Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091734 · ClinicalTrials.gov registry record · Phase 2
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
A Phase 2 study of Lipodystrophy, Partial, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07091734: Recruiting Phase 2 study of Lipodystrophy, Partial, sponsored by University of Michigan.
NCT07091734 is a Phase 2 study of Lipodystrophy, Partial that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07091734, a Phase 2 study of Lipodystrophy, Partial, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Primary Outcome
Height and weight will be collected to calculate BMI.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Usual care medications
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What NCT07091734 shows while recruiting
NCT07091734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Lipodystrophy, Partial appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07091734 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07091734 about?
NCT07091734 is a clinical study titled "Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024". This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study...
What is the current status of trial NCT07091734?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-09-08. Estimated completion is 2029-09.
What conditions does trial NCT07091734 study?
This clinical trial studies the following conditions: Lipodystrophy, Partial.
What interventions are being tested in trial NCT07091734?
The interventions under investigation include: Tirzepatide (DRUG), Usual care medications (DRUG).
Who is sponsoring clinical trial NCT07091734?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091734 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07091734's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI